
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. has demonstrated positive advancements in its clinical program for lorundrostat, reporting a significant placebo-adjusted blood pressure reduction of 9.1 mmHg at six weeks and 11.7 mmHg at twelve weeks in uncontrolled and resistant hypertension patients. The medication's safety profile is notably favorable, with a hyperkalemia rate of only 1.1% at the optimized dosing, indicating its potential for daily use among patients despite existing antihypertensive therapies. Additionally, the data suggests a robust efficacy of 8-12 mmHg blood pressure improvement, which positions lorundrostat as a viable treatment option and enhances the overall outlook for Mineralys Therapeutics in the biopharmaceutical market.
Bears say
Mineralys Therapeutics Inc. reported a significant net loss of $48.9 million for the fourth quarter of 2024 and a total net loss of $177.8 million for the entire year, reflecting ongoing financial challenges. The company faces substantial risks, including the possibility that its developmental candidate, lorundrostat, may not meet commercial revenue estimates, which could be affected by market conditions and pricing strategies. Additionally, there are concerns regarding the company’s ability to secure sufficient capital to fund operations and advance its program development and commercialization efforts.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares